Immune Checkpoint Blockade with Anti-PD-L1 Prevents Immune Dysfuntion and CLL Development in the TCL1 Adoptive Transfer Mouse Model

被引：0
|
作者：
Hanna, Bola [1 ]
McClanahan, Fabienne [1 ,2 ]
Clear, Andrew James [3 ]
Miller, Shaun [2 ]
Lichter, Peter [1 ]
Seiffert, Martina [1 ]
Gribben, John G. [3 ]
机构：
[1] German Canc Res Ctr, Heidelberg, Germany
[2] Barts Canc Inst, London, England
[3] Queen Mary Univ London, Barts Canc Inst, London, England
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Photo-induced crosslinked and anti-PD-L1 peptide incorporated liposomes to promote PD-L1 multivalent binding for effective immune checkpoint blockade therapy
    Youngjoo Lee
    Sukyung Song
    Suah Yang
    Jinseong Kim
    Yujeong Moon
    Nayeon Shim
    Hong Yeol Yoon
    Sehoon Kim
    Man Kyu Shim
    Kwangmeyung Kim
    Acta Pharmaceutica Sinica B, 2024, 14 (03) : 1428 - 1440
  • [22] Timing Anti-PD-L1 Checkpoint Blockade Immunotherapy to Enhance Tumor Irradiation
    Lee, Steve Seung-Young
    Pagacz, Joanna
    Averbek, Sera
    Scholten, David
    Liu, Yue
    Kron, Stephen J.
    CANCERS, 2025, 17 (03)
  • [23] Photo-induced crosslinked and anti-PD-L1 peptide incorporated liposomes to promote PD-L1 multivalent binding for effective immune checkpoint blockade therapy
    Lee, Youngjoo
    Song, Sukyung
    Yang, Suah
    Kim, Jinseong
    Moon, Yujeong
    Shim, Nayeon
    Yoon, Hong Yeol
    Kim, Sehoon
    Shim, Man Kyu
    Kim, Kwangmeyung
    ACTA PHARMACEUTICA SINICA B, 2024, 14 (03) : 1428 - 1440
  • [24] PD-L1 immune checkpoint blockade in genetically engineered mouse models of prostate cancer
    Shimizu, Nobutaka
    De Velasco, Marco A.
    Kura, Yurie
    Sakai, Kazuko
    Sugimoto, Kouichi
    Nozawa, Masahiro
    Yoshimura, Kazuhiro
    Yoshikawa, Kazuhiro
    Nishio, Kazuto
    Uemura, Hirotsugu
    CANCER SCIENCE, 2018, 109 : 292 - 292
  • [25] Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor
    Vandeveer, Amanda J.
    Fallon, Jonathan K.
    Tighe, Robert
    Sabzevari, Helen
    Schlom, Jeffrey
    Greiner, John W.
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (05) : 452 - 462
  • [26] Phytochemicals in regulating PD-1/PD-L1 and immune checkpoint blockade therapy
    Zhang, Qi
    Yang, Chenying
    Gao, Xingsu
    Dong, Ju
    Zhong, Caiyun
    PHYTOTHERAPY RESEARCH, 2024, 38 (02) : 776 - 796
  • [27] PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
    Hartkopf, Andreas D.
    Taran, Florin-Andrei
    Wallwiener, Markus
    Walter, Christina B.
    Kraemer, Bernhard
    Grischke, Eva-Maria
    Brucker, Sara Y.
    BREAST CARE, 2016, 11 (06) : 385 - 390
  • [28] Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy
    Song, Yue
    Li, Zhaoming
    Xue, Weili
    Zhang, Mingzhi
    IMMUNOTHERAPY, 2019, 11 (06) : 515 - 529
  • [29] The gastrointestinal microbiome and its composition are critical for antitumor efficacy of immune checkpoint inhibition by anti-PD-L1
    Cuiffo, Benjamin G.
    Parello, Caitlin S.
    Ritchie, Chelsea
    Pedrick, Katie
    Kury, Alexandra
    Costa, Catarina
    Van Dam, Brett
    Jung, Jonathan
    Lyng, Gregory D.
    Sonis, Stephen T.
    CANCER RESEARCH, 2017, 77
  • [30] PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade Therapy
    Cottrell, Tricia R.
    Taube, Janis M.
    CANCER JOURNAL, 2018, 24 (01): : 41 - 46
12345